Changes in Provision of Recommended Cardiac Care for Duchenne Muscular Dystrophy Using a Longitudinal Cohort
Name:
andrews_muscle_nerve_manuscrip ...
Embargo:
2027-05-19
Size:
1.935Mb
Format:
PDF
Description:
Final Accepted Manuscript
Affiliation
Department of Pediatrics, University of ArizonaIssue Date
2026-05-19
Metadata
Show full item recordPublisher
WileyCitation
J. G.Andrews, B. L.Heikke, O.Meziab, K.Mathews, C.Westfield, the MD STARnet, “Changes in Provision of Recommended Cardiac Care for Duchenne Muscular Dystrophy Using a Longitudinal Cohort,” Muscle & Nerve (2026): 1–10, https://doi.org/10.1002/mus.70257.Journal
Muscle & nerveRights
© 2026 Wiley Periodicals LLC.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Introduction/Aims Cardiac disease remains the leading cause of mortality in Duchenne muscular dystrophy (DMD), spurring release of cardiovascular supervision guidelines in 2005, 2010, 2018 and most recently, 2025. Little is known about changes in cardiac care after the updates to cardiac care recommendations for DMD. This study compares provision of recommended cardiac care before and after publication of the 2010 DMD Care Considerations. Methods Data from MD STARnet for individuals with DMD with at least one visit between March 1, 2010, through March 31, 2016 were used to assess frequency of cardiac visits stratified by age interval, diagnosis age, or left ventricular function (LVF) severity status. Data compared care received from February 2005 through February 2010 and March 2010 through March 2016. Results We assessed data for 922 individuals. Key findings overall demonstrate a significant increase in baseline assessments at diagnosis (39.5%–52.4%, p < 0.05), asymptomatic follow-up cardiac assessments every other year through 10 (22.1%–36.0%, p < 0.001) and annually age 11+ years (6.0%–18.1%, p < 0.001) and semi-annually for individuals with LVF abnormality (0.6%–1.4%, p < 0.01). There was no change in LVF assessment following new onset sinus tachycardia (ST). Arrhythmia, excluding ST, triggered investigation with a Holter in the post-guidelines period only (14.2%). Discussion We show increases in timing and frequency of cardiac care following publication of the 2010 Care Considerations. Areas for future research include understanding the relationship between adherence and cardiac outcomes, and barriers to receiving guideline-based care to ensure equitable DMD management.Note
12 month embargo; published 19 May 2026EISSN
1097-4598PubMed ID
42157332Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1002/mus.70257
Scopus Count
Collections
Related articles
- Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
- Authors: Bourke JP, Bueser T, Quinlivan R
- Issue date: 2018 Oct 16
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
- Authors: Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P
- Issue date: 2022 Feb 1
- Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy.
- Authors: Villa CR, Czosek RJ, Ahmed H, Khoury PR, Anderson JB, Knilans TK, Jefferies JL, Wong B, Spar DS
- Issue date: 2015 Dec 31
- Vesicoureteral Reflux.
- Authors: Leslie SW, Aeddula NR
- Issue date: 2026 Jan
- Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
- Authors: Garegnani L, Hyland M, Roson Rodriguez P, Escobar Liquitay CME, Franco JV
- Issue date: 2021 Nov 8